Literature DB >> 12390053

Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient.

Timothy F Murphy1, Sanjay Sethi.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a common problem in the elderly. The disease is characterised by intermittent worsening of symptoms and these episodes are called acute exacerbations. The best estimate, based on several lines of evidence, is that approximately half of all exacerbations are caused by bacteria. These lines of evidence include studies of lower respiratory tract bacteriology during exacerbations, correlation of airways' inflammation with results of sputum cultures during exacerbations, analysis of immune responses to bacterial pathogens, and the observation in randomised, prospective, placebo-controlled trials that antibacterial therapy is of benefit. The most important bacterial causes of exacerbations of COPD are nontypeable Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and Chlamydia pneumoniae. In approaching the elderly patient with an exacerbation, it is useful to consider the severity of the exacerbation based on three cardinal symptoms: increased sputum volume, increased sputum purulence and increased dyspnoea compared with baseline. Patients experiencing moderate (two symptoms) or severe (all three symptoms) exacerbations benefit from antibacterial therapy. Consideration of underlying host factors allows for a rational choice of antibacterial agent. Patients are considered to have 'simple COPD' or 'complicated COPD' based on: (i) the severity of underlying lung disease; (ii) the frequency of exacerbations; and (iii) the presence of comorbid conditions. It is proposed that patients with simple COPD are treated with doxycycline, a newer macrolide, or an extended-spectrum oral cephalosporin; and patients with complicated COPD are treated with amoxicillin/clavulanate or a fluoroquinolone. The major goals of antibacterial therapy for exacerbations of COPD are acceleration of symptom resolution and prevention of the complications of exacerbation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390053     DOI: 10.2165/00002512-200219100-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  65 in total

Review 1.  Guidelines for the treatment of acute exacerbations of chronic bronchitis.

Authors:  R F Grossman
Journal:  Chest       Date:  1997-12       Impact factor: 9.410

2.  Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.

Authors:  S G Adams; J Melo; M Luther; A Anzueto
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

Review 3.  Role of infection in chronic bronchitis.

Authors:  I Tager; F E Speizer
Journal:  N Engl J Med       Date:  1975-03-13       Impact factor: 91.245

4.  Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media.

Authors:  R Dagan; A Hoberman; C Johnson; E L Leibovitz; A Arguedas; F V Rose; B R Wynne; M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2001-09       Impact factor: 2.129

Review 5.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

6.  Role of infection in chronic bronchitis.

Authors:  D W Gump; C A Phillips; B R Forsyth; K McIntosh; K R Lamborn; W H Stouch
Journal:  Am Rev Respir Dis       Date:  1976-04

7.  Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis.

Authors:  K Yi; S Sethi; T F Murphy
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

8.  Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease.

Authors:  L Von Hertzen; H Alakärppä; R Koskinen; K Liippo; H M Surcel; M Leinonen; P Saikku
Journal:  Epidemiol Infect       Date:  1997-04       Impact factor: 2.451

9.  Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

Authors:  S Chodosh; A Schreurs; G Siami; H W Barkman; A Anzueto; M Shan; H Moesker; T Stack; S Kowalsky
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

10.  Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.

Authors:  E Monsó; J Ruiz; A Rosell; J Manterola; J Fiz; J Morera; V Ausina
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

View more
  19 in total

1.  A novel zinc binding system, ZevAB, is critical for survival of nontypeable Haemophilus influenzae in a murine lung infection model.

Authors:  Charles V Rosadini; Jeffrey D Gawronski; Daniel Raimunda; José M Argüello; Brian J Akerley
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

2.  ArcA-regulated glycosyltransferase lic2B promotes complement evasion and pathogenesis of nontypeable Haemophilus influenzae.

Authors:  Sandy M S Wong; Frank St Michael; Andrew Cox; Sanjay Ram; Brian J Akerley
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

3.  Expression of type IV pili by Moraxella catarrhalis is essential for natural competence and is affected by iron limitation.

Authors:  Nicole R Luke; Amy J Howlett; Jianqiang Shao; Anthony A Campagnari
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Differential genome contents of nontypeable Haemophilus influenzae strains from adults with chronic obstructive pulmonary disease.

Authors:  Matthew M Fernaays; Alan J Lesse; Sanjay Sethi; Xueya Cai; Timothy F Murphy
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

5.  Mucosal immunization of mice with recombinant OMP P2 induces antibodies that bind to surface epitopes of multiple strains of nontypeable Haemophilus influenzae.

Authors:  K L Ostberg; M W Russell; T F Murphy
Journal:  Mucosal Immunol       Date:  2008-10-29       Impact factor: 7.313

6.  Competitive inhibition of amino acid uptake suppresses chlamydial growth: involvement of the chlamydial amino acid transporter BrnQ.

Authors:  Peter R Braun; Hesham Al-Younes; Joscha Gussmann; Jeannette Klein; Erwin Schneider; Thomas F Meyer
Journal:  J Bacteriol       Date:  2007-11-16       Impact factor: 3.490

7.  The periplasmic disulfide oxidoreductase DsbA contributes to Haemophilus influenzae pathogenesis.

Authors:  Charles V Rosadini; Sandy M S Wong; Brian J Akerley
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

Review 8.  Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management.

Authors:  Don Hayes; Keith C Meyer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Outer membrane protein P5 is required for resistance of nontypeable Haemophilus influenzae to both the classical and alternative complement pathways.

Authors:  Charles V Rosadini; Sanjay Ram; Brian J Akerley
Journal:  Infect Immun       Date:  2013-11-25       Impact factor: 3.441

10.  Identification of a novel two-partner secretion locus in Moraxella catarrhalis.

Authors:  Pascale Plamondon; Nicole R Luke; Anthony A Campagnari
Journal:  Infect Immun       Date:  2007-04-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.